EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.264
https://www.valueinhealthjournal.com/article/S1098-3015(22)00465-X/fulltext
Section Title :
Section Order :
10234
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00465-X&doi=10.1016/j.jval.2022.04.264